chartexchange

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire Inc. | Nov 5, 2026 4:01 PM EST

BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today reported financial results for the quarter ended September 30, 2026, and provided recent corporate and clinical updates.

Read original article